CEDARHURST, N.Y., Nov. 4, 2021 /PRNewswire/ — The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Bristol-Myers Squibb Company (“BMS” or “the Company”) (NYSE: BMY), if they received Contingent Value Rights (“CVRs”) (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS’ acquisition of Celgene on November 20, 2019. Shareholders have until December 6, 2021 to file lead plaintiff applications in the securities class action lawsuit.
Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/filing-deadline–kuznicki-law-pllc-announces-class-action-on-behalf-of-shareholders-of-bristol-myers-squibb-company—bmy-301417325.html
SOURCE Kuznicki Law PLLC